Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

MabCure presents ovarian cancer diagnostic blood test study results at SGO meeting

USPTO grants new patent to Intellect's Alzheimer's vaccine

USPTO grants new patent to Intellect's Alzheimer's vaccine

Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions

Compugen reports positive results from CGEN-25068 in animal model to treat certain disease conditions

Neoprobe reports positive feedback from FDA for RIGScan development

Neoprobe reports positive feedback from FDA for RIGScan development

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

USPTO grants patent to Symphogen's Sym004 to treat solid tumors

U-M scientists identify potential target to treat aggressive prostate cancer

U-M scientists identify potential target to treat aggressive prostate cancer

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Millennium, Seattle commence brentuximab vedotin phase I trial in patients with ALCL

Cummings School granted U.S. Patent for antibody-based treatment against Hemolytic Uremic Syndrome

Cummings School granted U.S. Patent for antibody-based treatment against Hemolytic Uremic Syndrome

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

biOasis completes selection of monoclonal antibodies in Cognitest program for Alzheimer's disease

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Arsanis closes Series A financing for $10 million

Arsanis closes Series A financing for $10 million

FUJIFILM enters definitive agreement to acquire Merck

FUJIFILM enters definitive agreement to acquire Merck

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

New fully human monoclonal antibodies to battle Chikungunya

New fully human monoclonal antibodies to battle Chikungunya

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan 2010 total revenue increases 5% to $1,169.7 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.